Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Johnson & Johnson Could Serve As High-Yield Bond Alternative
06:36am, Saturday, 11'th Jan 2025
Johnson & Johnson remains a "Buy" for its stability and consistent dividends, despite short-term price fluctuations and modest growth expectations. Q3 2024 results showed a 5.2% sales increase but a s
JNJ ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Johnson & Johnson investment
04:15pm, Friday, 10'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible viol
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). In
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
01:15pm, Friday, 10'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson. ("J&J" or the "Company") (NYSE:JNJ).
What To Expect From JNJ Stock In 2025?
11:19am, Friday, 10'th Jan 2025
Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like E
FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab
09:25am, Friday, 10'th Jan 2025
JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
09:00am, Friday, 10'th Jan 2025
You will want to build your portfolio the right way if you're going to make money with stocks over the long haul. You wouldn't build your house on a shaky foundation, would you?
2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid
04:51am, Friday, 10'th Jan 2025
The second year of Wall Street's bull market rally didn't disappoint, with all three major stock indexes hitting fresh all-time highs. This includes the ageless Dow Jones Industrial Average (^DJI 0.25
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
10:01am, Thursday, 09'th Jan 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
J&J Pauses Sales of Atrial Fibrillation Device, Stock Down
09:35am, Thursday, 09'th Jan 2025
J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.
Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis
08:04am, Thursday, 09'th Jan 2025
Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positiv
J&J pauses rollout of heart device in the US to investigate stroke risk
02:24pm, Wednesday, 08'th Jan 2025
Johnson & Johnson said on Wednesday that it has temporarily paused the rollout of its Varipulse heart device in the United States, citing an abundance of caution as the company investigates four repor
J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product
01:44pm, Wednesday, 08'th Jan 2025
Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system. The post J&J Falls — While Boston Scientific, Medtronic Pop — After Stroke
Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer
12:13pm, Wednesday, 08'th Jan 2025
The latest dividend declarations, combined with stock price movements, have pushed PFE's yield to be almost twice as JNJ's. But I want to caution you to look beyond yield (and P/E too) and examine oth
Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J's com
